Biotechnology and Bioprocess Engineering:BBE

  • 제7권2호
  • /
  • Pages.67-75
  • /
  • 2002
  • /
  • 1226-8372(pISSN)
  • /
  • 1976-3816(eISSN)
한국생물공학회 (The Korean Society for Biotechnology and Bioengineering)
권호 표지

A Novel Simple Method to Purify Recombinant Soluble Human Complement Receptor Type 1 (sCR 1) from CHO Cell Culture

  • Wang, Pi-Chao (Institute of Applied Biochemistry, Tsukuba University) ;
  • Hisamune Kato (Institute of Applied Biochemistry, Tsukuba University) ;
  • Takehiro Inoue (Institute of Applied Biochemistry, Tsukuba University) ;
  • Masatoshi Matsumura (Institute of Applied Biochemistry, Tsukuba University) ;
  • Noriyuki Ishii (Biological Information Research Center, National Institute of Advanced Industrial Science and Technology) ;
  • Yoshinobu Murakami (Institute for Frontier Medical Science Kyoto University) ;
  • Tsukasa Seya (Department of immunology, Osaka Medical Center fro Cancer and Cardiovascular Disease)
  • 발행 : 2002.03.01
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

The human complement receptor type 1 (CR 1, C3 b/C4b receptor) is a polymorphic membrane glycoprotein expressed on human erythrocytes, peripheral leukocytes, plasma and renal glomerular podocytes, which consists of transmembrane and cytoplasmic domains with 30 repeating homologous protein domains known as short consensus repeats (SCR). CR1 has been used as an inhibitor for inflammatory and immune system for the past several years. Recently; it is reported that CRl was found to suppress the hyper-acute rejection in xeno-transplantation and can be used to cure autoimmune diseases. A soluble form of CRl, called sCRl, is a recombinant CRl by cleaving the transmembrane domain at C-terminus and has been expressed in Chinese Hamster Ovary (CHO) cells. Several purification methods for sCR1 from CHO cells have been reported, but most of them require complicated steps at high cost. Moreover, such methods are mostly performed under the pH condition apt to denaturing sCR1 and causes sCRl losing its activity. We here report a rapid and efficient method to purify sCR1 from CHO cell. The new method consists of a two-stage of cell culture by cultivating cells in serum medium followed by serum-free medium, and a two-stage of column purification by means of heparin and gel filtration column chromatography. By using this novel method, sCR1 can be purified in a simple and effective way with high yield and purity, furthermore, the purified sCR1 was confirmed to retain its activity to suppress the complement activation in vivo and ex vivo.

키워드

참고문헌

  1. J. Exp. Med. v.165 Human C3b/C4b receptor (CR1). Demonstration of long homologous repeating domains that are composed of the short consensus repeats characteristics of C3/C4 binding proteins Klickstein, L.B.;W.W. Wong;J.A. Smith;J.H. Weis;J.G. Wilson;D.T. Fearon https://doi.org/10.1084/jem.165.4.1095
  2. J. Exp. Med. v.168 Identification of distinct C3b and C4b recognition sites in the human C3b/C4b receptor (CR1, CD35) by deletion mutagenesis Klickstein, L.B.;Bartow, T.J.;V. Miletic;L.D. Rabson;J.A. Smith;D.T. Fearon https://doi.org/10.1084/jem.168.5.1699
  3. J. Exp. Med. v.168 Identification of an alternative polyadenylation site in the human C3b/C4b receptor (complement receptor type 1) transcriptional unit and prediction of a secreted form of complement receptor type 1 Hourcade, D.;D.R. Miesner;J.P. Atkinson;V.M. Holers https://doi.org/10.1084/jem.168.4.1255
  4. Science v.249 Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflam-mation and necrosis Weisman, H.F.;T. Bartow;M.K. Leppo;H.C. Jr. Marsh;G.R. Carson;M.F. Concino;M.P. Boyle;K.H. Roux;M.L. Weisfeldt;D.T. Fearon https://doi.org/10.1126/science.2371562
  5. J. Immunol. v.146 Recombinant soluble human complement receptor type 1 inhibits inflammation in the reversed passive arthus reaction in rats Yeh, C.G.;H.C. Jr. Marsh;G.R. Carson;L. Berman;M.F. Concino;S.M. Scesney;R.E. Kuestner;R. Skibbens;K.A. Donahue;S.H. Ip
  6. J. Immunol. v.148 Protective effects of soluble CR1 in complement and neutrophil-mediated tissue injury Mulligan, M.S.;C.G. Yeh;A.R. Rudolph;P.A. Ward
  7. Transplantation v.57 The effect of soluble complement receptor type 1 on hyper-acute rejection of porcine xenografts Pruitt, S.K.;A.D. Kirk;R.R. Bollinger;H.C. Jr. Marsh;B.H. Collins;J.L. Levin;J.R. Mault;J.S. Heinle;S. Ibrahim;A.R. Rudolph https://doi.org/10.1097/00007890-199402150-00009
  8. Neurosci. Lett. v.200 Soluble complement receptor type 1 inhibits experimental autoimmune neuritis in Lewis rats Jung, S.;K.V. Toyka;H.P. Hartung https://doi.org/10.1016/0304-3940(95)12115-K
  9. J. Neuroimmunol. v.71 Soluble complement receptor 1 (sCR1) protects against experimental autoimmune myasthenia gravis Piddlesden, S.J.;S. Jiang;J.L. Levin;A. Vincent;B.P. Morgan https://doi.org/10.1016/S0165-5728(96)00144-0
  10. Transpl. Immunol. v.6 Prevention of hyperacute rejection by phosphatidylinositol- anchored mini-complement receptor type 1 Mikata, S.;S. Miyagawa;M. Yoshitatsu;M. Ikawa;M. Okabe;H. Matsuda;R. Shirakura https://doi.org/10.1016/S0966-3274(98)80025-7
  11. Eur. J. Immunol. v.26 A soluble deletion mutant of the human complement receptor type 1, which lacks the C4b binding site, is a selective inhibitor of the alternative complement pathway Scesney, S.M.;S.C. Makrides;M.L. Gosselin;P.J. Ford;B.M. Andrews;E.G. Hayman;H.C. Jr. Marsh https://doi.org/10.1002/eji.1830260810
  12. J. Biol. Chem. v.274 Recombinant glycoproteins that inhibit complement activation and also bind the selectin adhesion molecules Rittershaus, C.W.;L.J. Thomas;D.P. Miller;M.D. Picard;K.M. Geoghegan-Barek;S.M. Scesney;L.D. Henry;A.C. Sen;A.M. Bertino;G. Hannig;H. Adari;R.A. Mealey;M.L. Gosselin;M. Couto;E.G. Hayman;J.L. Levin;V.N. Reinhold;H.C. Jr. Marsh https://doi.org/10.1074/jbc.274.16.11237
  13. J. Immunol. v.146 Proposed structure of the F' allotype of human CR1. Loss of a C3b binding site may be associated with altered function Wong, W.W.;S.A. Farrell
  14. J. Biochem. Biophys. Methods. v.32 Rapid purification of human complement receptor type 1 (CD35, CR1) Seya, T.;M. Matsumoto;M. Hatanaka, M.;Okada, T.;Masaki;K. Iida https://doi.org/10.1016/0165-022X(95)00005-C
  15. Nature v.227 Cleavage of structural proteins during the assembly of the head of bacteriophage T4 Laemmli, U.K. https://doi.org/10.1038/227680a0
  16. J. Immunol. v.134 Polymorphism of the C3b/C4b receptor (CR1): characterization of a fourth allele Dykman, T.R.;J.A. Hatch;M.S. Aqua;J.P. Atkinson
  17. Biochim. Biophys. Acta v.1289 Factor H co-purifies with thrombospondin isolated from platelet secretate Carron, J.A.;R.C. Bates;A.I. Smith;T. Tetoz;A. Arellano;D.L. Gordon;G.F. Burns https://doi.org/10.1016/0304-4165(95)00095-X
  18. J. Biosci. Bioeng. v.89 Direct refolding of recombinant human growth differntiation factor 5 for large-scale production process Honda, J.;H. Andou;T. Mannen;S. Sugimoto https://doi.org/10.1016/S1389-1723(00)80061-4
  19. J. Immunol. v.153 Primary sequence of an alternatively spliced form of CR1. Candidate for the 75.000 M(r) complement receptor expressed on chimpanzee erythrocytes Birmingham, D.J.;X.P. Shen;D. Hourcade;M.W. Nickells;J.P. Atkinson
  20. Clin. Exp. Immunol. v.112 Mapping epitopes for 20 monoclonal antibodies to CR1 Nickells, M.;R. Hauhart;M. Krych;V.B. Subramanian;K. Geoghegan-Barek;H.C. Jr. Marsh;J.P. Atkinson https://doi.org/10.1046/j.1365-2249.1998.00549.x
  21. J. Immunol. v.144 Demonstration in human plasma of a form of C3 that has the conformation of "C3b-like C3" Hack, C.E.;J. Paardekooper;F. Van Milligen
  22. Mol. Immunol. v.28 Regulatory system of guinea-pig complement C3b: tests for compatibility of guinea-pig factors H and I with human factors Seya, T.;M. Okada;K. Hazeki;S. Nagasawa https://doi.org/10.1016/0161-5890(91)90150-I
  23. J. Exp. Med. v.188 Complement dependent clearance of apoptotic cells by human macrophages Mevorach, D.;J.O. Mascarenhas;D. Gershov;K.B. Elkon https://doi.org/10.1084/jem.188.12.2313
  24. Xenoiransplantation v.8 Effect of cell surface concentration of human DAF on transgenic pig aortic endothelial cells on the degree of protection afforded against human complement deposition Carrington, C.A.;G. dos Santos Cruz https://doi.org/10.1034/j.1399-3089.2001.00086.x
  25. FEMS Immunol. Med. Microbiol. v.31 Protection of xenogeneic cells from human complement-mediated lysis by the expression of human DAF, CD59 and MCP Huang, J.;D. Gou;C. Zhen;D. Jiang;X. Mao;W. Li;S. Chen;C. Cai https://doi.org/10.1111/j.1574-695X.2001.tb00521.x
  26. Hum. Cell. v.4 Cultivation of mammalian cells in serum-free media Umeda, M.
  27. Vitro Cell Dev. Biol. Anim. v.37 Establishment of a human hepatocyte line (OUMS-29) having CYP 1A1 and 1A2 activities from fetal liver tissue by transfection of SV40 LT Fukaya, K.;S. Asahi;S. Nagamori;M. Sakaguchi;C. Gao;M. Miyazaki;M. Namba https://doi.org/10.1007/BF02577541
  28. Vitro Cell Dev. Biol. Anim. v.33 Heparan sulfate is required for interaction and activation of the epithelial cell fibroblast growth factor receptor-2Ⅲb with stromal-derived fibroblast growth factor-7 Jang, J.H.;F. Wang;M. Kan https://doi.org/10.1007/s11626-997-0162-7
  29. Blood v.98 Purification of human von Willebrand factorcleaving protease and its identification as a new member of the metalloproteinase family Fujikawa, K.;H. Suzuki;B. McMullen;D. Chung https://doi.org/10.1182/blood.V98.6.1662
  30. J. Clin. Invest. v.99 Heparan Sulfate Proteoglycans of the Cardiovascular System Rosenberg, R.D.;N.W. Shworak;J. Liu;L. Zhang https://doi.org/10.1172/JCI119377
  31. J. Hepatol. v.30 Active form of human hepatocyte growth factor is excreted into bile after hepatobiliary resection Kurumiya, Y.;Y. Nimura;E. Takeuchi;K. Nozawa;M. Nagino;A. Hayata;A. Maeda;S. Yoshida https://doi.org/10.1016/S0168-8278(99)80004-X
  32. J. Chromatogr. B. Biomed. Sci. Appl. v.737 Preparative two-step purification of recombinant human basic fibroblast growth factor from high-cell-density cultivation of Escherichia coli Garke, G.;W.D. Deckwer;F.B. Anspach https://doi.org/10.1016/S0378-4347(99)00394-1
  33. Biotechnol. Appl. Biochem. v.33 Improved preparation and crystallization of 25 kDa human fibroblast growth factor-9 Koyama, N.;H. Ohmae;S. Tsuji;Y. Tanaka;T. Kurokawa;O. Nishimura https://doi.org/10.1042/BA20000075
  34. J. Immunol. v.135 Purification and functional analysis of the polymorphic variants of the C3b/C4b receptor (CR1) and comparison with H, C4b-binding protein (C4bp), and decay accelerating factor(DAF) Seya, T.;V.M. Holers;J.P. Atkinson
  35. Ann. Thorac. Surg. v.63 Attenuation of changes in leukocyte surface markers and complement activation with heparin-coated cardiopulmonary bypass Moen, O.;K. Hogasen;E. Fosse;E. Dregelid;V. Brockmeier;P. Venge;M. Harboe;T.E. Mollnes https://doi.org/10.1016/S0003-4975(96)00743-6
  36. Artif. Organs v.24 Effects of new polymer-coated extracorporeal circuits on biocompatibility during cardiopulmonary bypass Saito, N.;S. Motoyama;J. Sawamoto https://doi.org/10.1046/j.1525-1594.2000.06520.x
  37. J. Immunol. v.126 Isolation of C4-binding protein from guinea pig plasma and demonstration of its function as a control protein of the classical complement pathway C3 convertase Skerl, K.G.;R.A. Calderone;T. Sreevalsan;J. Burge;A. Nicholson-Weller;K.F. Austen
  38. J. Immunol. v.126 Murine C4-binding protein: a rapid purification method by affinity chromatography Kaidoh, T.;S. Natsuume-Sakai;M. Takahashi
  39. Int. Immunopharmacol v.1 C4bp binding to porin mediates stable serum resistance of Neisseria gonorrhoeae Ram, S.;M. Cullinane;A.M. Blom;S. Gulati;D.P.;McQuillen;R. Boden;B.G. Monks;C.O. Connell;C. Elkins;M.K. Pangburn;B. Dahlback;P.A. Rice https://doi.org/10.1016/S1567-5769(00)00037-0
  40. Biochim. Biophys. Acta v.1289 Factor H co-purifies with thrombospondin isolated from platelet secretate Carron, J.A.;R.C. Bates;A.I. Smith;T. Tetoz;A. Arellano;D.L. Gordon;G.F. Burns https://doi.org/10.1016/0304-4165(95)00095-X
  41. J. Immunol. Methods v.202 Effects of thrombospondin purified by heparin affinity or ion-exchange chromatography on the alternative complement pathway Scott, P.E.;D.B. Purkall;S. Ruddy https://doi.org/10.1016/S0022-1759(97)00006-9
  42. J. Pharmacol. Exp. Ther. v.281 Activation of the alternative pathway of complement by a phos-phorothioate oligonucleotide: potential mechanism of action Henry, S.P.;P.C. Giclas;J. Leeds;M. Pangburn;C. Auletta;A.A. Levin;D.J. Kornbrust
  43. J. Biol. Chem. v.264 Factor J: Isolation and characterization of a new polypeptide inhibitor of complement C1 Lopez-Trascasa, M.;D.H. Bing;M. Rivard;A. Nicholson-Weller
  44. J. Cell Biol. v.130 Heparin is an adhesive ligand for the leukocyte integrin Mac-1 (CD11b/CD1) Diamond, M.S.;R. Alon;C.A. Parkos;M.T. Quinn;T.A. Springer https://doi.org/10.1083/jcb.130.6.1473
  45. Circulation v.100 Heparin inhibits ligand binding to the leukocyte integrin Mac-1 (CD11b/CD18) Peter, K.;M. Schwarz;C. Conradt;T. Nordt;M. Moser;W. Kubler;C. Bode https://doi.org/10.1161/01.CIR.100.14.1533
  46. Artif. Organs v.16 C3a and C5a anaphylatoxins bind to heparin-based sorbent in low density lipoprotein apheresis: in vitro and in vivo investigations Sinitsyn, V.V.;E.T. Bokchubaev;A.G. Mamontova;N.V. Ovtrakht;E.L. Nasonov;G.A. Konovalov;V.V. Kukharchuk https://doi.org/10.1111/j.1525-1594.1992.tb00312.x
  47. Blood v.96 Induction of decay-accelerating factor by thrombin through a protease-activated receptor 1 and protein kinase C-dependent pathway protects vascular endothelial cells from complement-mediated injury Lidington, E.A.;D.O. Haskard;J.C. Mason